Search

IJMSC: Impact of Shared Decision Making on Disease-Modifying Drug Adherence in MS

Target Audience

The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

1) Describe new approaches to optimize adherence through shared decision-making and patient engagement principles.

2) Integrate shared decision-making principles and models into clinical practice.

Accreditation and Credit Statements

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit

The CMSC designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Credit

The CMSC designates this enduring material for 1.0 contact hour (1.0 in the area of pharmacology).

Disclosures

Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has received royalties from Springer Publishing, served on a speakers’ bureau for Biogen, and done contracted research for Adamas Pharmaceuticals.

Laurie Scudder, DNP, NP, has served as a reviewer for this activity. She has disclosed no relevant financial relationships.

Aliza Ben-Zacharia, DNP, ANP, MSCN, has received consulting fees from Biogen, Bayer, EMD Serono, Celgene, Novartis, Genentech, and Genzyme; and research grants from Biogen and Novartis.

Meagan Adamson, DNP, FNP-BC, MSCN, has served on speakers’ bureaus for Biogen, EMD Serono, Genentech, Novartis, Genzyme, Acorda, Teva, and Mallinckrodt.

Allison Boyd, MPAS, PA-C, MSCS, has received consulting fees from Genzyme; served on a speakers’ bureau/advisory board for EMD Serono; and has been a speaker for Teva Neurosciences and Biogen.

Paula Hardeman, MPAS, PA-C, has disclosed no relevant financial relationships.

Jennifer Smrtka, MSN, ARNP-C, MSCN, has served on advisory boards for Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva Neuroscience and as a speaker for EMD Serono, Genentech, Mallinckrodt, Sanofi Genzyme, and Teva Neuroscience; she receives salary from Biogen.

Bryan Walker, MHS, PA-C, has received consulting fees from Biogen, EMD Serono, and Sanofi Genzyme; and served on speakers’ bureau for Novartis and Biogen.

Tracy Walker, FNP-C, WOCN, MSCN, has received grant support from EMD Serono, Genzyme, and Teva; personal fees from Acorda, Genentech, Sanofi Genzyme, Mallinckrodt, and Teva; and served on speakers’ bureaus for EMD Serono, Acorda, Teva, and Genzyme.

One peer reviewer for the IJMSC has received consulting fees from and participated on speakers’ bureaus for Biogen, Novartis, Genentech, Sanofi Genzyme, and EMD Serono. The other peer reviewer has disclosed no relevant financial relationships.

The staff at the IJMSC, CMSC, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships.

Note: Financial relationships for some authors may have changed in the interval between listing these disclosures and publication of the article.

Method of Participation

Release Date: December 1, 2018

Valid for Credit Through: December 1, 2019

In order to receive CME/CNE credit, participants must:

  1. Review the CME/CNE information, including learning objectives and author disclosures.
  2. Study the educational content.
  3. Complete the post-test and evaluation.

Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This CME/CNE activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the authors and do not necessarily represent the views of CMSC or Delaware Media Group.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health-care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Instructions for Completing the Post Test and Claiming Credit

To complete the post-test, evaluation and claim credit, please click on the To Claim Credit button below or go to: www.highmarksce.com/mscare/.

Log in with your user name and password*, or create a new account.

Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.

*If you forgot your username or password, click on Forgot password. Your login credentials will be emailed to you.

Contact Information

If you have questions about this CME/CNE activity, please contact the CMSC at [email protected] or 201-487-1050.